Health Care Technology
Opzira, Inc. Launches To Advance Ophthalmic Diagnostics With Innovative Medical Device Portfolio
.png?ext=.png "Business Wire"){kind=small}
Share
MIDDLETOWN, Pa.--(BUSINESS WIRE)--#eyecare--OpZira™, Inc., a forward-thinking ophthalmic medical device company founded on a legacy of research excellence, today announced its official formation. OpZira is dedicated to delivering innovative technologies that enhance the detection and monitoring of ocular disease, empowering clinicians with advanced diagnostic tools.
OpZira’s creation follows Alcon’s acquisition of LumiThera (https://www.alcon.com/media-release/alcon-completes-acquisition-lumithera/) and its innovative Valeda® Light Delivery System, the first and only FDA-authorized treatment for dry age-related macular degeneration (AMD). As part of the transaction, LumiThera’s diagnostic product lines were spun off to LumiThera shareholders, leading to the establishment of OpZira, Inc.
OpZira’s product portfolio includes:
- AdaptDx Pro® – A wearable dark adaptometer that leverages AI to ensure a consistent patient experience. Impaired dark adaptation speed, a key early indicator of rod-mediated dysfunction, is often among the first functional signs of retinal disease. AdaptDx Pro is available in the U.S.
- NOVA™ Vision Testing System – A robust electrophysiology platform providing objective assessments of the entire visual and neuro-visual pathway. The Visual Evoked Potential (VEP) module is available in the U.S. and select international markets, while the Electroretinography (ERG) module is available outside the U.S.
“Building on the LumiThera team’s success in developing the Valeda treatment for early to intermediate dry AMD patients, the OpZira technologies may provide early detection and ongoing monitoring which are important for optimizing patient outcomes,” stated Eleonora Lad, MD, PhD, Duke University Medical Center. “Now that there are approved treatment options for dry AMD, having tools that provide objective data to help determine when and how often to treat patients is critical.”
“OpZira was founded to bridge the gap between groundbreaking research and practical clinical tools,” said Clark Tedford, PhD, President & CEO of OpZira. “Our mission is to give eye care professionals the technology they need to detect ocular diseases earlier and monitor them more effectively.”
About OpZira
OpZira, Inc. is a forward-thinking ophthalmic medical device company founded on a legacy of research excellence. The company delivers innovative technologies designed to enhance the detection and monitoring of ocular disease. For more information, visit OpZira.com.
Contacts
Frequently Asked Questions
What is OpZira?
OpZira is an ophthalmic medical device company focused on innovative technologies for detecting and monitoring ocular diseases.
What products does OpZira offer?
OpZira offers AdaptDx Pro, a wearable dark adaptometer, and the NOVA Vision Testing System, an electrophysiology platform for objective visual assessments.
How does OpZira's technology benefit patients?
OpZira's technology enables earlier detection and more effective monitoring of eye diseases, leading to improved patient outcomes.
First published on Thu, Sep 4, 2025
Enjoyed what you've read so far? Great news - there's more to explore!
Stay up to date with the latest news, a vast collection of tech articles including introductory guides, product reviews, trends and more, thought-provoking interviews, hottest AI blogs and entertaining tech memes.
Plus, get access to branded insights such as informative white papers, intriguing case studies, in-depth reports, enlightening videos and exciting events and webinars from industry-leading global brands.
Dive into TechDogs' treasure trove today and Know Your World of technology!
Disclaimer - Reference to any specific product, software or entity does not constitute an endorsement or recommendation by TechDogs nor should any data or content published be relied upon. The views expressed by TechDogs' members and guests are their own and their appearance on our site does not imply an endorsement of them or any entity they represent. Views and opinions expressed by TechDogs' Authors are those of the Authors and do not necessarily reflect the view of TechDogs or any of its officials. While we aim to provide valuable and helpful information, some content on TechDogs' site may not have been thoroughly reviewed for every detail or aspect. We encourage users to verify any information independently where necessary.
Loading comments...